
Sanofi makes a pre-JP Morgan splash with Kymab
The Kymab takeover represents another bold move as the French company bids to rebuild its pipeline.

Go or no go? Johnson & Johnson awaits Spravato nod
Others hoping to get FDA approvals include Sage Therapeutics and Novartis, but hopes look dimmer for Lexicon and Sanofi.